Literature DB >> 7628045

Intracellular glutathione and cytotoxicity of platinum complexes.

L Pendyala1, P J Creaven, R Perez, J R Zdanowicz, D Raghavan.   

Abstract

Although there have been a number of reports correlating cellular GSH levels with cytotoxicity of platinum agents, none has examined the relationship between GSH concentrations and cytotoxicity. In this study, using a highly specific HPLC method for measuring GSH and expressing GSH as concentration and also per cell number, we evaluated the correlation between GSH levels and the cytotoxicity to five agents in ten human tumor cell lines. The five platinum agents included the platinum(II) complexes cisplatin, carboplatin and oxaliplatin and platinum(IV) complexes iproplatin and tetraplatin. The correlation between intracellular GSH concentration and cytotoxicity was highly significant only for iproplatin (P = 0.002) followed by tetraplatin, which demonstrated a trend toward statistical significance (P = 0.06). Cytotoxicity of the other platinum complexes showed no relation to GSH concentration, cisplatin itself showing a P-value of 0.09. In contrast, the GSH levels normalized to cell number showed a statistically significant correlation with the cytotoxicity of four of the five platinum agents, the exception being carboplatin; the strongest correlation observed was that for iproplatin and tetraplatin. Glutathione-S-transferase (GST) activity in these cell lines showed no correlation with cytotoxicity of any of the platinum complexes. Our results, from the analyses of both GSH concentration as well as GSH per cell number, suggest a significantly higher interaction between GSH and iproplatin compared with the other platinum agents. Moreover, our data suggest that relationships between cytotoxicity and GSH levels on a per-cell basis may not persist when differences in cell volume are taken into account.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7628045     DOI: 10.1007/BF00689042

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  42 in total

1.  DNA binding of iproplatin and its divalent metabolite cis-dichloro-bis-isopropylamine platinum (II).

Authors:  L Pendyala; A V Arakali; P Sansone; J W Cowens; P J Creaven
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Long term culture of normal and neoplastic human glia.

Authors:  J Pontén; E H Macintyre
Journal:  Acta Pathol Microbiol Scand       Date:  1968

3.  Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.

Authors:  B C Behrens; T C Hamilton; H Masuda; K R Grotzinger; J Whang-Peng; K G Louie; T Knutsen; W M McKoy; R C Young; R F Ozols
Journal:  Cancer Res       Date:  1987-01-15       Impact factor: 12.701

4.  Increase in gamma-glutamylcysteine synthetase activity and steady-state messenger RNA levels in melphalan-resistant DU-145 human prostate carcinoma cells expressing elevated glutathione levels.

Authors:  H H Bailey; J J Gipp; M Ripple; G Wilding; R T Mulcahy
Journal:  Cancer Res       Date:  1992-09-15       Impact factor: 12.701

5.  Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds.

Authors:  C Meijer; N H Mulder; H Timmer-Bosscha; W J Sluiter; G J Meersma; E G de Vries
Journal:  Cancer Res       Date:  1992-12-15       Impact factor: 12.701

6.  An unexpected biotransformation pathway for tetrachloro-(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in the L1210 cell line.

Authors:  S G Chaney; G R Gibbons; S D Wyrick; P Podhasky
Journal:  Cancer Res       Date:  1991-02-01       Impact factor: 12.701

7.  In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin.

Authors:  L Pendyala; P J Creaven
Journal:  Cancer Res       Date:  1993-12-15       Impact factor: 12.701

Review 8.  Glutathione metabolism and its role in hepatotoxicity.

Authors:  L D DeLeve; N Kaplowitz
Journal:  Pharmacol Ther       Date:  1991-12       Impact factor: 12.310

9.  The role of metallothionein, glutathione, glutathione S-transferases and DNA repair in resistance to platinum drugs in a series of L1210 cell lines made resistant to anticancer platinum agents.

Authors:  M Hrubisko; A T McGown; B W Fox
Journal:  Biochem Pharmacol       Date:  1993-01-07       Impact factor: 5.858

10.  An in vitro study comparing the cytotoxicity of three platinum complexes with regard to the effect of thiol depletion.

Authors:  E Smith; A P Brock
Journal:  Br J Cancer       Date:  1988-06       Impact factor: 7.640

View more
  8 in total

1.  A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group study.

Authors:  Orren Beaty; Stacey Berg; Susan Blaney; Marcio Malogolowkin; Mark Krailo; Ronald Knight; Paula Schaiquevich; Clinton Stewart; Zhengjia Chen; Marvin Nelson; Stephan Voss; S Percy Ivy; Peter C Adamson
Journal:  Pediatr Blood Cancer       Date:  2010-09       Impact factor: 3.167

Review 2.  Oxaliplatin: pharmacokinetics and chronopharmacological aspects.

Authors:  F Lévi; G Metzger; C Massari; G Milano
Journal:  Clin Pharmacokinet       Date:  2000-01       Impact factor: 6.447

Review 3.  Oxaliplatin: a review of its use in the management of metastatic colorectal cancer.

Authors:  L R Wiseman; J C Adkins; G L Plosker; K L Goa
Journal:  Drugs Aging       Date:  1999-06       Impact factor: 3.923

Review 4.  Growth factors, glia and gliomas.

Authors:  M Noble; M Mayer-Pröschel
Journal:  J Neurooncol       Date:  1997-12       Impact factor: 4.130

Review 5.  Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.

Authors:  C R Culy; D Clemett; L R Wiseman
Journal:  Drugs       Date:  2000-10       Impact factor: 9.546

Review 6.  Anticancer activity of metal complexes: involvement of redox processes.

Authors:  Ute Jungwirth; Christian R Kowol; Bernhard K Keppler; Christian G Hartinger; Walter Berger; Petra Heffeter
Journal:  Antioxid Redox Signal       Date:  2011-05-11       Impact factor: 8.401

7.  In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473.

Authors:  J Holford; S Y Sharp; B A Murrer; M Abrams; L R Kelland
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

8.  Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione levels.

Authors:  F I Raynaud; D E Odell; L R Kelland
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.